Skip to main content
October 05, 2019
SAN DIEGO—A year’s treatment with the investigational drug ALKS 3831 was generally well-tolerated and demonstrated a safety profile that supports long-term use, according to study findings presented at Psych Congress 2019.
October 05, 2019
SAN DIEGO—Cannabidiol (CBD) has quickly entered the mainstream, but there is a dearth of evidence about the effects of the cannabis byproduct, a speaker told a large audience at Psych Congress 2019.
October 05, 2019
SAN DIEGO—The opioid withdrawal drug lofexidine demonstrated statistically significant efficacy across a half-dozen patient- and clinician-reported outcomes during the first 7 days after immediate opioid cessation, according to study presented at Psych Congress 2019.
October 05, 2019
SAN DIEGO—Children with bipolar disorder who were treated with lurasidone had a lower risk of all-cause and psychiatric-related hospitalization than those treated with aripiprazole or olanzapine, according to a retrospective claims database study.
October 05, 2019
SAN DIEGO—People with binge eating disorder are at increased risk of suicidal ideation and suicide attempt—and that risk appears even greater if they also have attention-deficit/hyperactivity disorder or have had bariatric surgery.​​​​​​​
October 04, 2019
SAN DIEGO—Clinicians tend to decrease monotherapy and increase adjunctive therapy when patients with major depressive disorder experience major depressive episodes, according to research presented at Psych Congress 2019.
October 04, 2019
SAN DIEGO—When added to ongoing treatment, pimavanserin significantly improved sexual function in patients with major depressive disorder, according to study results shared during poster sessions at Psych Congress 2019.
October 04, 2019
SAN DIEGO—Added to standard-of-care treatment, esketamine nasal spray rapidly reduced depressive symptoms in patients at imminent risk of suicide, according to two phase 3 trials presented at Psych Congress 2019.
October 04, 2019
SAN DIEGO—Mindfulness meditation is an effective, evidence-based treatment which can improve symptoms of anxiety, depression, and other mental health conditions, two speakers told attendees at a Psych Congress 2019 session.
October 04, 2019
SAN DIEGO—Prescribers who may be seeing an increase in patients with stimulant use disorders are still left relying on off-label treatment options with limited evidence of effectiveness, a researcher told a Psych Congress audience.
Back to Top